AngioDynamics Stock Price, News & Analysis (NASDAQ:ANGO)

AngioDynamics trades on the NASDAQ under the ticker symbol "ANGO."

AngioDynamics, Inc. (NASDAQ:ANGO) announced its quarterly earnings data on Thursday, October, 3rd. The medical instruments supplier reported $0.08 earnings per share for the quarter, beating analysts' consensus estimates of $0.04 by $0.04. The medical instruments supplier had revenue of $66 million for the quarter, compared to analyst estimates of $67.74 million. AngioDynamics had a return on equity of 4.89% and a net margin of 17.79%. The company's revenue was up 3.3% on a year-over-year basis. During the same period in the prior year, the company earned $0.16 earnings per share. View AngioDynamics' Earnings History.

AngioDynamics is scheduled to release their next quarterly earnings announcement on Friday, January 3rd 2020. View Earnings Estimates for AngioDynamics.

AngioDynamics issued an update on its FY20 earnings guidance on Thursday, October, 3rd. The company provided EPS guidance of $0.10-0.15 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.26. The company issued revenue guidance of $280-286 million, compared to the consensus revenue estimate of $281.89 million.

2 equities research analysts have issued 1 year price objectives for AngioDynamics' stock. Their forecasts range from $21.00 to $23.00. On average, they anticipate AngioDynamics' share price to reach $22.00 in the next year. This suggests a possible upside of 49.5% from the stock's current price. View Analyst Price Targets for AngioDynamics.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AngioDynamics in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AngioDynamics.

Media headlines about ANGO stock have trended somewhat positive this week, according to InfoTrie Sentiment. The research group scores the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. AngioDynamics earned a coverage optimism score of 0.8 on InfoTrie's scale. They also gave news headlines about the medical instruments supplier a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for AngioDynamics.

AngioDynamics saw a decline in short interest in September. As of September 30th, there was short interest totalling 1,130,000 shares, a decline of 17.5% from the August 30th total of 1,370,000 shares. Based on an average daily trading volume, of 235,900 shares, the short-interest ratio is currently 4.8 days. Approximately 3.1% of the company's shares are sold short. View AngioDynamics' Current Options Chain.

Some companies that are related to AngioDynamics include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Becton Dickinson and (BDX), Intuitive Surgical (ISRG), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), IDEXX Laboratories (IDXX), ResMed (RMD), Teleflex (TFX), DexCom (DXCM), Hologic (HOLX), Steris (STE) and Varian Medical Systems (VAR).

Based on aggregate information from My MarketBeat watchlists, some companies that other AngioDynamics investors own include Oasis Petroleum (OAS), General Electric (GE), Intel (INTC), Mattel (MAT), Chesapeake Energy (CHK), Centurylink (CTL), DIGITAL RLTY TR/SH (DLR), Hanesbrands (HBI), Kimco Realty (KIM) and Regions Financial (RF).

AngioDynamics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Tributary Capital Management LLC (1.80%), Envestnet Asset Management Inc. (0.17%), Assenagon Asset Management S.A. (0.15%), Strs Ohio (0.09%), State of Alaska Department of Revenue (0.08%) and Brinker Capital Inc. (0.07%). Company insiders that own AngioDynamics stock include Kevin J Gould and Michael Greiner. View Institutional Ownership Trends for AngioDynamics.

ANGO stock was sold by a variety of institutional investors in the last quarter, including Tributary Capital Management LLC, Brinker Capital Inc. and Strs Ohio. Company insiders that have sold AngioDynamics company stock in the last year include Kevin J Gould and Michael Greiner. View Insider Buying and Selling for AngioDynamics.

ANGO stock was purchased by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Meeder Asset Management Inc., State of Alaska Department of Revenue, Pacer Advisors Inc., Nisa Investment Advisors LLC, Campbell & CO Investment Adviser LLC and Envestnet Asset Management Inc.. View Insider Buying and Selling for AngioDynamics.

Shares of ANGO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ANGO stock can currently be purchased for approximately $14.72.

AngioDynamics has a market capitalization of $553.77 million and generates $359.48 million in revenue each year. The medical instruments supplier earns $61.34 million in net income (profit) each year or $0.83 on an earnings per share basis. AngioDynamics employs 1,050 workers across the globe.View Additional Information About AngioDynamics.

The official website for AngioDynamics is http://www.angiodynamics.com/.

AngioDynamics' mailing address is 14 PLAZA DRIVE, LATHAM NY, 12110. The medical instruments supplier can be reached via phone at 518-795-1400 or via email at [email protected]